回生口服液改善癌症患者围化疗期便秘临床疗效研究

摘要

Objective To investigate the efficacy of Huisheng oral solution to treat constipation in cancer patients during chemotherapy and possible adverse reactions .Methods Seventy-five patients with constipation after chemother-apy were enrolled in the current study .They were randomly assigned into a treatment group in which 39 patients received Huisheng oral solution and a control group in which 36 patients were administrated with lactulose oral solution .Each group was given 30 ml of solution per time , three times per day for two weeks .Then they were subject to the following as-sessments before and after treatment: constipation symptoms and general signs , therapeutic efficacy , disease outcomes ( Karnofsky scores ) , overall self -evaluation and adverse reactions .Results After administration , patients in both groups presented remarkably improved clinical symptoms and general sign scores compared with pre -treatment levels ( P=0.000), in which the treatment group produced superior outcomes to the control (P=0.026).However, no signifi-cant difference was seen between both groups as to therapeutic efficacy (P=0.261) and overall self -evaluation (P=0.495).For adverse reactions, nausea and vomiting, leukopenia, thrombocytopenia, low hemoglobin and thrombosis ap-peared less frequently in the treatment group than the control (P<0.05), rather than diarrhea, hepatic and renal func-tion, skin rashes and peripheral neuropathy (P>0.05).Conclusion Huisheng oral solution can relieve symptoms re-lated to constipation in cancer patients during chemotherapy , with less adverse reactions , which is worthwhile to apply on a large scale in clinical setting .%目的：观察回生口服液治疗癌症患者围化疗期便秘的临床疗效及不良反应。方法采用分组对照的研究方法，选取化疗后出现便秘症状的患者75例，分为治疗组（39例）和对照组（36例）。治疗组患者饭后服用回生口服液，对照组患者饭后服用乳果糖口服液，2组服药均一次30 ml，一日3次，持续2周为1个疗程。观察2组患者治疗前后便秘临床症状及体征评分变化、便秘的疗效、疾病转归（ Karnofsky评分）、总体自我评价及不良反应。结果治疗后2组患者便秘的临床症状及体征评分均较治疗前降低，差异均有统计学意义（ P＝0．000）；治疗组疾病转归优于对照组，差异有统计学意义（P＝0．026）；2组便秘疗效（P＝02．61）、总体自我评价（P＝0．495）比较，差异均无统计学意义；治疗组恶心呕吐、白细胞减少、血小板减少、血红蛋白减少及血栓发生率少于对照组，差异有统计学意义（P＜0．05）；2组腹泻、肝肾功能损害、皮疹、周围神经病变发生率的差异无统计学意义（P ＞0．05）。结论回生口服液可以改善癌症患者围化疗期便秘症状，且不良反应少，值得临床推广。